Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Percentage of Participants Achieving Virological Response at End of Treatment

Virologic response was defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than 50 IU/mL.

Time frame: End of treatment (week 12 or 24 depending on the treatment regimen)

Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 12 Weeks Post-treatment

Sustained virologic response was defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than 50 IU/mL 12 weeks after the last dose of study drug. The Core Population with sufficient follow-up data regarding SVR12 included all core population participants who * had evaluable HCV RNA data ≥ 70 days after the last actual dose of the ABBVIE REGIMEN * or a HCV RNA value ≥ 50 IU/mL at the last measurement post-baseline * or had HCV RNA \< 50 IU/mL at the last measurement post-baseline, but no HCV RNA measurement ≥ 70 days after the last actual dose of the ABBVIE REGIMEN due to reasons related to safety (e.g. dropped out due to adverse event) or virologic failure.

Time frame: 12 weeks after the last dose of study drug (week 24 or 36 depending on the treatment regimen)

Percentage of Participants With Relapse

Relapse was defined as participants with a virologic response (VR; HCV RNA \< 50 IU/mL) at end of treatment (EOT) followed by HCV RNA ≥ 50 IU/mL at any time after the end of treatment.

Time frame: End of treatment (week 12 or 24 depending on the treatment regimen) and up to 24 weeks after the end of treatment.

Percentage of Participants With Breakthrough

Breakthrough was defined as at least one documented HCV RNA \< 50 IU/mL followed by HCV RNA ≥ 50 IU/mL during treatment.

Time frame: 12 or 24 weeks (depending on the treatment regimen)

Percentage of Participants in Each Non-response Category 12 Weeks Post-treatment

SVR12 non-response was categorized according to the following: * On-treatment virologic failure (breakthrough \[at least one documented HCV RNA \< 50 IU/mL followed by HCV RNA ≥ 50 IU/mL during treatment\] or failure to suppress \[each measured on-treatment HCV RNA value ≥ 50 IU/mL\]); * Relapse, defined as HCV RNA \< 50 IU/mL at EOT followed by HCV RNA ≥ 50 IU/mL post-treatment in patients who completed treatment (not more than 7 days shortened); * Premature treatment discontinuation with no on-treatment virologic failure; * Missing SVR12 data and/or none of the above criteria.

Time frame: 12 weeks after the last dose of study drug (week 24 or 36 depending on the treatment regimen)

Percentage of the Direct Acting Antiviral (DAA) Dose Taken in Relation to the Target Dose of DAA

Adherence to study treatment was calculated as: Cumulative dose taken / (initial prescribed dose \* planned duration)

Time frame: From first dose of study drug to end of treatment, 12 to 24 weeks depending on the treatment regimen.

Percentage of the Ribavirin Dose Taken in Relation to the Target Dose of Ribavirin

Adherence to study treatment was calculated as: Cumulative dose taken / (initial prescribed dose \* planned duration)

Time frame: From first dose of study drug to end of treatment, 12 to 24 weeks depending on the treatment regimen

Percentage of Ribavirin (RBV) Treatment Days in Relation to the Target Number of Ribavirin Treatment Days

Time frame: From first dose of study drug to end of treatment, 12 to 24 weeks depending on the treatment regimen.

Number of Participants With Adverse Events, Serious Adverse Events, or Pregnancies

Time frame: From first dose of study drug through 30 days after last dose (16 weeks).

Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score

The EQ-5D-5L is a health state utility instrument that evaluates preference for health status. The 5 items in the EQ-5D-5L comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on 5 levels of severity (1: indicating no problem, 2: indicating slight problems, 3: indicating moderate problems, 4: indicating severe problems, 5: indicating extreme problems), and a separate visual analog scale (VAS). Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score by applying country-specific weights.The range for EQ-5D-5L index score is 0 to 1 where '0' is defined as a health state equivalent to being dead and '1' is full health.The higher the score the better the health status.

Time frame: Baseline, end of treatment (week 12 or 24 depending on the treatment regimen), and at 12 and 24 weeks after end of treatment

Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS Score

The EQ-5D-5L is a health state utility instrument that evaluates preference for health status with a separate visual analog scale (VAS). The VAS assesses overall health on a scale from 0 (worst health imaginable) to 100 (best health imaginable).

Time frame: Baseline, end of treatment (week 12 or 24 depending on the treatment regimen), and at 12 and 24 weeks after end of treatment

Change From Baseline in Work Productivity and Activity Impairment (WPAI): Absenteeism

The WPAI Hepatitis C V2.0 is an HCV specific questionnaire used to measure work absenteeism, work presenteeism, and daily activity impairment. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity. Absenteeism indicates the percentage of work time missed due to health problems.

Time frame: Baseline, end of treatment (week 12 or 24 depending on the treatment regimen), and at 12 and 24 weeks after end of treatment